Advertisement
BMY vs PFE
Which Stock Would AI Choose? Bristol-Myers Squibb (BMY) vs. Pfizer (PFE) Stock Comparison
Key Takeaways
- BMY has outperformed PFE in recent market activity, with stronger monthly gains around 12% compared to PFE's approximately 6%.
- Both stocks offer attractive dividends, but PFE yields higher at about 6.3% versus BMY's 4.1%.
- BMY benefits from positive analyst initiations like Barclays' Overweight rating and pipeline progress in oncology and multiple myeloma.
- PFE shows growth in oncology approvals and obesity drug deals, though facing revenue decline projections.
- Year-to-date, BMY leads with roughly 16% gains over PFE's 9%.
- Market caps are comparable, with BMY at $125B and PFE at $152B, reflecting similar large-cap pharma positioning.
Introduction
Bristol-Myers Squibb (BMY) and Pfizer (PFE) represent two pillars of the biopharmaceutical sector, both focused on oncology, immunology, and innovative therapies amid patent cliffs and pipeline transitions. This stock comparison analyzes their recent performance, growth drivers, and market positioning in the current environment. Traders seeking momentum plays and investors hunting dividend stability or undervalued pharma exposure will find value here, as both navigate competitive pressures while leveraging robust drug portfolios for relative outperformance against broader indices.
BMY Overview and Recent Performance
Bristol-Myers Squibb (BMY), a global biopharmaceutical leader, specializes in oncology, hematology, immunology, and cardiovascular treatments. Its portfolio includes blockbusters like Eliquis and Opdivo, supported by a growth segment now approaching 60% of sales. In recent weeks, BMY shares have shown resilience, posting over 12% monthly gains and year-to-date advances near 16%, trading around $61 with a 52-week range of $42.52-$63.33. Sentiment has lifted on FDA acceptance of the iberdomide NDA with Priority Review for multiple myeloma, positive Reblozyl trial data in alpha-thalassemia, and analyst upgrades including Barclays' Overweight at $75. These catalysts, alongside a 2026 revenue outlook of $46B-$47.5B, have driven outperformance despite looming patent expirations.
PFE Overview and Recent Performance
Pfizer (PFE), a diversified biopharma giant, excels in oncology, vaccines, and rare diseases with products like Eliquis (co-marketed with BMY), Prevnar, and emerging GLP-1 assets. Recent market activity saw PFE shares rise about 6% monthly and 9% year-to-date, hovering near $27 in a 52-week range of $20.92-$27.94. Key influences include FDA full approval for the BRAFTOVI regimen in colorectal cancer, a $495M obesity drug deal in China, and Q4 earnings beats, though tempered by revenue decline forecasts through 2030. Analyst views are mixed, with some citing insurmountable patent cliffs, yet the high dividend yield supports defensive positioning.
Trending AI Robots
Tickeron's Trending AI Robots page showcases a curated selection from hundreds of AI trading bots that analyze thousands of tickers across stocks, ETFs, and crypto. Only the top performers, suited to current market conditions, earn a spot in this dynamic section. These bots deliver impressive stats, including annualized returns up to +253.60%, win rates as high as 94.92%, and profit factors reaching 35.36, with trade durations from 5 minutes to days and low drawdowns in select strategies. Diverse approaches—such as swing trading dips, hedging downturns, or volatility plays on leveraged ETFs—cater to various risk profiles and timeframes. Explore these brokerage-tested algorithms to enhance your trading edge in today's volatile markets.
Head-to-Head Comparison
BMY and PFE share sector exposure in oncology and immunology but diverge in growth trajectories and risks. BMY's business model emphasizes pipeline diversification, with recent catalysts like iberdomide boosting momentum, while PFE leans on broader revenue from vaccines and partnerships, including obesity expansions. Recent momentum favors BMY with superior YTD and monthly returns, reflecting stronger sentiment from analyst upgrades versus PFE's cautious outlooks amid steeper revenue declines. Risk factors include patent cliffs for both, but BMY appears better positioned with lower beta (0.29 vs. 0.44) and growth portfolio momentum. PFE counters with higher EBITDA and dividend appeal, trading at a premium PE (19.7 vs. 17.7), highlighting trade-offs in yield versus upside potential.
Tickeron AI Verdict
Tickeron's AI currently leans toward BMY based on trend consistency, recent outperformance, pipeline catalysts like iberdomide Priority Review, and relative stability in recent market activity. While PFE offers superior yield and oncology approvals, its projected revenue headwinds reduce probabilistic edge. This positioning suggests higher near-term favorability for BMY among momentum-oriented strategies.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full Disclaimers and Limitations.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BMY is a Hold and PFE is a Hold.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
BMY’s FA Score shows that 1 FA rating(s) are green whilePFE’s FA Score has 0 green FA rating(s).
- BMY’s FA Score: 1 green, 4 red.
- PFE’s FA Score: 0 green, 5 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
BMY’s TA Score shows that 3 TA indicator(s) are bullish while PFE’s TA Score has 4 bullish TA indicator(s).
- BMY’s TA Score: 3 bullish, 7 bearish.
- PFE’s TA Score: 4 bullish, 4 bearish.
Price Growth
BMY (@Pharmaceuticals: Major) experienced а -0.86% price change this week, while PFE (@Pharmaceuticals: Major) price change was 0.00% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was -0.07%. For the same industry, the average monthly price growth was -0.76%, and the average quarterly price growth was +6.45%.
Reported Earning Dates
BMY is expected to report earnings on Apr 30, 2026.
PFE is expected to report earnings on May 05, 2026.
Industries' Descriptions
@Pharmaceuticals: Major (-0.07% weekly)The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.
| BMY | PFE | BMY / PFE | |
| Capitalization | 120B | 155B | 77% |
| EBITDA | 15.2B | 16.8B | 90% |
| Gain YTD | 11.739 | 11.148 | 105% |
| P/E Ratio | 17.04 | 20.01 | 85% |
| Revenue | 48.2B | 62.6B | 77% |
| Total Cash | N/A | 13.6B | - |
| Total Debt | 47.1B | 64B | 74% |
BMY | PFE | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 56 | 75 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 39 Fair valued | 34 Fair valued | |
PROFIT vs RISK RATING 1..100 | 82 | 100 | |
SMR RATING 1..100 | 23 | 74 | |
PRICE GROWTH RATING 1..100 | 48 | 38 | |
P/E GROWTH RATING 1..100 | 68 | 35 | |
SEASONALITY SCORE 1..100 | n/a | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
PFE's Valuation (34) in the Pharmaceuticals Major industry is in the same range as BMY (39). This means that PFE’s stock grew similarly to BMY’s over the last 12 months.
BMY's Profit vs Risk Rating (82) in the Pharmaceuticals Major industry is in the same range as PFE (100). This means that BMY’s stock grew similarly to PFE’s over the last 12 months.
BMY's SMR Rating (23) in the Pharmaceuticals Major industry is somewhat better than the same rating for PFE (74). This means that BMY’s stock grew somewhat faster than PFE’s over the last 12 months.
PFE's Price Growth Rating (38) in the Pharmaceuticals Major industry is in the same range as BMY (48). This means that PFE’s stock grew similarly to BMY’s over the last 12 months.
PFE's P/E Growth Rating (35) in the Pharmaceuticals Major industry is somewhat better than the same rating for BMY (68). This means that PFE’s stock grew somewhat faster than BMY’s over the last 12 months.
| BMY | PFE | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 55% | N/A |
| Stochastic ODDS (%) | 1 day ago 60% | 1 day ago 61% |
| Momentum ODDS (%) | 1 day ago 56% | 1 day ago 51% |
| MACD ODDS (%) | 1 day ago 51% | 1 day ago 55% |
| TrendWeek ODDS (%) | 1 day ago 54% | 1 day ago 55% |
| TrendMonth ODDS (%) | 1 day ago 56% | 1 day ago 51% |
| Advances ODDS (%) | 8 days ago 53% | 1 day ago 56% |
| Declines ODDS (%) | 4 days ago 53% | 7 days ago 57% |
| BollingerBands ODDS (%) | 1 day ago 50% | 1 day ago 56% |
| Aroon ODDS (%) | 1 day ago 56% | 1 day ago 51% |
Advertisement
BMY and
Correlation & Price change
A.I.dvisor indicates that over the last year, BMY has been loosely correlated with PFE. These tickers have moved in lockstep 65% of the time. This A.I.-generated data suggests there is some statistical probability that if BMY jumps, then PFE could also see price increases.
| Ticker / NAME | Correlation To BMY | 1D Price Change % | ||
|---|---|---|---|---|
| BMY | 100% | +1.85% | ||
| PFE - BMY | 65% Loosely correlated | +0.11% | ||
| MRK - BMY | 62% Loosely correlated | -2.07% | ||
| AMGN - BMY | 58% Loosely correlated | +0.34% | ||
| ABBV - BMY | 55% Loosely correlated | +0.27% | ||
| BIIB - BMY | 54% Loosely correlated | -2.50% | ||
More | ||||